Posted by Michael Wonder on 27 Oct 2022
PMPRB finds ultra-rare drug Procysbi is excessively priced
26 October 2022 - On 1 September 2022, a Panel of the Patented Medicine Prices Review Board issued a decision that the price of Horizon Pharma’s Procysbi (cysteamine delayed release capsules) was and is excessive under sections 83 and 85 of the Patent Act.
The Panel ordered Horizon to reduce the price of Procysbi from $0.4140/mg to no higher than the Maximum Average Potential Price prescribed by the Moderate Improvement Test under the Guidelines ($0.2202/mg) and pay the excess revenues to Canada.
